- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02180919
Implementation of Telemonitoring in Chronic Heart or Lung Failure (TELECRAFT)
Implementation of Telemonitoring in the Management of Acute Exacerbations of Chronic Heart Failure and Respiratory Failure/Chronic Obstructive Pulmonary Disease
The aims of the study are to:
- Implement a telemonitoring programme in heart failure and obstructive pulmonary disease (COPD) /chronic respiratory patients by assessing the real world impact of on readmissions, consults, home visits, quality of life and economic endpoints.
- Explore the effects of telemonitoring across heart and respiratory groups with respect to i) factors that influence how patients integrate telemonitoring into their daily routines and self care behaviour and ii) how healthcare professionals use telemonitoring to aid decision- making.
- Understand the impact of telemonitoring on a variety of care pathways.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND
Heart failure exacerbations consume 60-70% of costs for the condition and COPD exacerbations lead to 1:8 admissions so are costly to the NHS. The roll-out of telemonitoring in chronic disease is in line with NHS policy (Building Telecare in England; High Quality Care for All, national health service (NHS) next stage Darzi review).
Despite systematic reviews, the Whole System Demonstrator programme and randomised control trial (RCT) evidence in heart failure, the outcome of implementing telemonitoring is unclear, the evidence base in COPD is less consistent, and few studies have included economic analysis or investigated cross speciality implementation. An Italian trial found that telemedicine reduces chronic respiratory admissions by a third, but the Italian health service differs from the united kingdom (UK) system. The european union (EU) Commission Communication on telemedicine 2009 has stressed the need for new deployments to contribute to the evidence base in respiratory disease, and include a detailed analysis of the process changes that determine success. Our group has previously shown that telemonitoring reduces unplanned admissions in heart failure patients, and that elderly patients were able to cope well with the equipment. The investigators have also had experience with telesupport in chronic respiratory patients.
RATIONALE FOR CURRENT STUDY
The study will assess the implementation of a telemonitoring programme to demonstrate
- whether home telemonitoring alerts patients and health professionals to exacerbations and reduces admissions,
- if it can be reasonably implemented cross specialty,
- the impact on quality of life of patients,
- interaction between healthcare professionals, robustness of algorithms and self efficacy in patients.
The cross-over design allows sustained effects on self care and admissions to be assessed after removal of telemonitoring at 6 months in first groups treated. The acceptability of telemonitoring to healthcare workers and factors aiding and limiting integration into care pathways will be explored. Results should inform the commissioning of telemonitoring locally/nationally, facilitate buy-in from secondary and primary care teams, and optimise cost.
OVERALL DESIGN
Design: Crossover implementation study with patients allocated randomly 1:1 to telemonitoring or delayed entry to telemonitoring (after 6 months). All patients with receive standard optimal medical care according to European Society of Cardiology (ESC) Heart Failure guidelines, National Institute for Health and Care Excellence (NICE) COPD guidelines or other best practice care pathways as relevant to their condition. Each patient will receive home telemonitoring for 6 months. Comparisons will be carried out between patients with delayed entry (controls) and active telemonitoring. In the group receiving telemonitoring in first 6 month period the investigators will be able to assess impact of withdrawal in subsequent 6 months ie longer term benefit.
TELEMONITORING
Data from the monitors are delivered to the health care team members personal computer (PCs) using a dedicated broad band line which is installed in the patients home and is routed via a secure Philips Server. Each patient receives education in using the device until he or she and/or family/carer are fully confident. Via information displayed on their television screen each day patients are requested to answer interactive questions on level of breathlessness, sleep quality, phlegm production, wheeze. These results from each patient is used to create a warning system such that if all parameters are satisfactory this will appear as a green light; or for example, if a drop in arterial oxygen saturation and increase in wheeze, or increase in weight and increased breathlessness is seen the Motiva system will generate a red light for that patient which needs to be acted upon. It is an interactive system and therefore the healthcare team member can advise the patient through their screen (eg. increase dose of diuretic or oxygen flow rate, start antibiotic and steroids), or provide educational material eg. on inhaler use or exercise, and patients can respond. Patients will also be asked several questions once a week on whether they have consulted their general practitioner (GP), visited an Accident and Emergency Dept or been admitted to hospital.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW3 6NP
- Royal Brompton Hospital
-
London, United Kingdom
- West Middlesex University Hospita
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Heart failure patients: age > 18 years who were in New York Heart Association class II-IV at time of discharge diagnosed by ESC guidelines.
- Respiratory patients: age > 18 years with diagnosis of COPD or respiratory insufficiency due to chronic respiratory disorder diagnosed by Consultant Respiratory Physician (eg. bronchiectasis, chest wall disease, neuromuscular disorder) and arterial oxygen saturation value during most recent admission for exacerbation of 90% or below (or partial pressure of oxygen in arterial blood (PaO2) 8.0 kilopascal (kPa) or below) on air, or who fulfill criteria for, and receive long term oxygen therapy.
Exclusion Criteria:
- Age <18 years.
- Cognitive impairment sufficient to interfere with use of telemonitoring system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control period
All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
|
|
EXPERIMENTAL: Telemonitoring
telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel.
Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily.
In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
|
Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel.
Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily.
In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first event
Time Frame: at 6 months
|
Acute admission coded as due to acute exacerbation of heart failure/COPD, respiratory failure or mortality from heart failure/respiratory failure/COPD.
|
at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance with telemonitoring
Time Frame: averaged over the expected 6 month period
|
Daily input into the Motiva system will be collected Monday to Friday.
At the end of the study period the compliance with inputting the data on a daily basis will be averaged.
This information will provide compliance with telemonitoring data.
|
averaged over the expected 6 month period
|
Self Efficacy
Time Frame: 0, 3, 6, 9 and 12 months
|
The COPD patients will be asked to complete the Bristol COPD Knowledge Questionnaire before and after the 6 month period of telemonitoring, and the heart failure patients invited to complete the Self Care of Heart Failure index before and after telemonitoring.
|
0, 3, 6, 9 and 12 months
|
Focus interviews
Time Frame: 6 and 12 months after completion of the study
|
Focus structured interviews will be carried out individually in the patient's home or at Royal Brompton Hospital after 6 and 12 months.
|
6 and 12 months after completion of the study
|
Health care contacts
Time Frame: 0,1,2,3,4,5,6,7,8,9,10,11 and 12 months
|
GP consultations, emergency room visits will be recorded monthly in a self reported questionnaire
|
0,1,2,3,4,5,6,7,8,9,10,11 and 12 months
|
Hospital Anxiety and Depression Score (HADS)
Time Frame: 0, 3, 6, 9 and 12 months
|
The HADS score determines the levels of anxiety and depression that a patient is experiencing.
The HADS is a fourteen item scale that generates ordinal data.
Seven of the items relate to anxiety and seven relate to depression.
|
0, 3, 6, 9 and 12 months
|
Minnesota Living with Heart Failure questionnaire
Time Frame: 0, 3, 6, 9 and 12 months
|
Minnesota Living with Heart Failure questionnaire measures the effects of symptoms, functional limitations, psychological distress on an individual's quality of life, the Minnesota Living with Heart Failure questionnaire asks each person to indicate using a 6-point, zero to five, Likert scale how much each of 21 facets prevented them from living as they desired
|
0, 3, 6, 9 and 12 months
|
The EuroQOL five dimensions questionnaire (EQ 5D)
Time Frame: 0, 3, 6, 9 and 12 months
|
The self-assessment questionnaire is self-reported description of the subject's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
The subject is asked to grade their own current level of function in each dimension into one of three degrees of disability (severe, moderate or none).
|
0, 3, 6, 9 and 12 months
|
Chronic Respiratory Disease Questionnaire (CRQ)
Time Frame: 0, 3, 6, 9 and 12 months
|
The CRQ is a self-reported, disease specific measurement tool to assess health related quality of life (HRQL) in patients with chronic respiratory disease.
Consists of 20 items across four dimensions: dyspnea, fatigue, emotional function, and mastery.
|
0, 3, 6, 9 and 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Anita K Simonds, MD, Royal Brompton & Harefield NHS Foundation Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10/H0704/19 (OTHER: Royal Brompton Hospital REC/research office)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on CE marked Philips Motiva system
-
Medtronic EndovascularCompletedVenous Insufficiency of LegUnited Kingdom, Denmark, Germany, Netherlands
-
University Hospital, GrenobleCommissariat A L'energie AtomiqueRecruitingHealthy Volunteers | Parkinson's Disease Patients | Para/Tetraplegic PatientsFrance
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingHealthy | Anxiety | Pain, Procedural | Gender | Nociceptive Pain | Pupillary Light Reflex LostSpain
-
Essential Medical, Inc.CompletedFemoral Arteriotomy ClosureNetherlands, Denmark, Finland, Switzerland, Canada
-
Medela AGCompleted
-
Umbria Bioengineering TechnologiesRecruitingBreast CancerSpain, Italy
-
Umbria Bioengineering TechnologiesCompletedBreast CancerItaly, Spain
-
Abbott Medical DevicesCompletedVentricular Fibrillation | Ventricular TachycardiaGermany, Greece
-
Charite University, Berlin, GermanyBoston Scientific Corporation; Deutsches Zentrum für Herz-Kreislauf-Forschung... and other collaboratorsRecruitingAtrial Fibrillation | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mildly Reduced Ejection FractionGermany
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted